SEC Comment Letter for Vistagen Therapeutics, Inc. (VTGN) (CIK 0001411685) (VTGN) — May 7, 2020
Vistagen Therapeutics, Inc. (VTGN) (CIK 0001411685)
Date: May 7, 2020 · CIK: 0001411685 · Accession: 0000000000-20-004027
AI Filing Summary & Sentiment
File numbers found in text: 333-237968
Letter
United States securities and exchange commission logo May 7, 2020 Shawn K. Singh Chief Executive Officer VistaGen Therapeutics, Inc. 343 Allerton Avenue South San Francisco, California 94080 Re:VistaGen Therapeutics, Inc. Registration Statement on Form S-3 Filed May 1, 2020 File No. 333-237968 Dear Mr. Singh: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jessica R. Sudweeks, Esq.
Show Raw Text
United States securities and exchange commission logo
May 7, 2020
Shawn K. Singh
Chief Executive Officer
VistaGen Therapeutics, Inc.
343 Allerton Avenue
South San Francisco, California 94080
Re:VistaGen Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 1, 2020
File No. 333-237968
Dear Mr. Singh:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jessica R. Sudweeks, Esq.